BioCentury
ARTICLE | Clinical News

SYL1001: Phase II started

March 11, 2013 7:00 AM UTC

Sylentis began a double-blind, placebo-controlled, Spanish Phase II trial to evaluate topical SYL1001 once daily for 10 days in 60 patients. ...